| 000 | 01718 a2200517 4500 | ||
|---|---|---|---|
| 005 | 20250513211230.0 | ||
| 264 | 0 | _c20000531 | |
| 008 | 200005s 0 0 eng d | ||
| 022 | _a0250-7005 | ||
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aGridelli, C | |
| 245 | 0 | 0 |
_aSingle agent docetaxel plus granulocyte-colony stimulating factor (G-CSF) in previously treated patients with advanced non small cell lung cancer. A phase II study and review of the literature. _h[electronic resource] |
| 260 |
_bAnticancer research _c |
||
| 300 |
_a1077-84 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial; Clinical Trial, Phase II; Journal Article; Multicenter Study; Review | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aAntineoplastic Agents, Phytogenic _xadverse effects |
| 650 | 0 | 4 |
_aCarcinoma, Non-Small-Cell Lung _xdrug therapy |
| 650 | 0 | 4 |
_aDeoxycytidine _xanalogs & derivatives |
| 650 | 0 | 4 | _aDocetaxel |
| 650 | 0 | 4 | _aDrug Administration Schedule |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aGranulocyte Colony-Stimulating Factor _xadverse effects |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aLung Neoplasms _xdrug therapy |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aNeoplasm Staging |
| 650 | 0 | 4 |
_aPaclitaxel _xadverse effects |
| 650 | 0 | 4 | _aSurvival Analysis |
| 650 | 0 | 4 | _aTaxoids |
| 650 | 0 | 4 | _aGemcitabine |
| 700 | 1 | _aFrontini, L | |
| 700 | 1 | _aBarletta, E | |
| 700 | 1 | _aRossi, A | |
| 700 | 1 | _aBarzelloni, M L | |
| 700 | 1 | _aScognamiglio, F | |
| 700 | 1 | _aGuida, C | |
| 700 | 1 | _aGatani, T | |
| 700 | 1 | _aFiore, F | |
| 700 | 1 | _aDe Bellis, M | |
| 700 | 1 | _aMarfella, A | |
| 700 | 1 | _aManzione, L | |
| 773 | 0 |
_tAnticancer research _gvol. 20 _gno. 2B _gp. 1077-84 |
|
| 999 |
_c10762242 _d10762242 |
||